Savara Inc. (NASDAQ:SVRA – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $5.60.
Several equities analysts recently commented on the stock. HC Wainwright downgraded shares of Savara from a “buy” rating to a “neutral” rating and cut their price target for the company from $6.00 to $2.00 in a report on Thursday, May 29th. Evercore ISI dropped their target price on shares of Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a research note on Wednesday, May 28th. Wells Fargo & Company lowered their target price on Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 28th. Finally, Guggenheim reaffirmed a “buy” rating and set a $8.00 price target (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th.
Check Out Our Latest Research Report on Savara
Savara Price Performance
Savara (NASDAQ:SVRA – Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Analysts predict that Savara will post -0.45 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Richard J. Hawkins purchased 48,225 shares of the business’s stock in a transaction on Friday, June 20th. The shares were bought at an average cost of $2.04 per share, with a total value of $98,379.00. Following the transaction, the director now owns 115,466 shares of the company’s stock, valued at approximately $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.33% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Savara
Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock valued at $25,512,000 after acquiring an additional 365,959 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company’s stock worth $482,000 after purchasing an additional 31,168 shares in the last quarter. Millennium Management LLC raised its position in shares of Savara by 71.8% during the 4th quarter. Millennium Management LLC now owns 482,263 shares of the company’s stock valued at $1,481,000 after buying an additional 201,599 shares during the period. Deutsche Bank AG raised its position in shares of Savara by 6.1% during the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company’s stock valued at $2,848,000 after buying an additional 53,054 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Savara by 314.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company’s stock valued at $217,000 after buying an additional 53,547 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.
About Savara
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Stories
- Five stocks we like better than Savara
- What is Short Interest? How to Use It
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- Manufacturing Stocks Investing
- 3 Stocks Hitting All-Time Highs With More Room to Run
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.